AML patients in the high-risk group showed a lower sensitivity to a range of anti-leukemia agents/drugs, including cytarabine, methotrexate, etoposide, and ABT-263 (a BCL-2 inhibitor, also called Navitoclax), while they responded better to several other drugs like rapamycin, bortezomib, Erlotinib, even though some of them are currently not in clinical use for treatment of AML. This evidence concerns the gene BCL2 and acute myeloid leukemia.